Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 357-368

  Vigne, Solenne ^a   Germi, Raphaële ^b   Duraffour, Sophie ^a,c   Larrat, Sylvie ^b   Andrei, Graciela ^c   Snoeck, Robert ^c   Garin, Daniel ^a,d   Crance, Jean Marc ^a  

^a CENTRE DE RECHERCHES   (France)

^b UNIV GRENOBLE ALPES   (France)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d Hôpital Inter Armées du Val de Grâce   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; MESSENGER RNA; SICONTROL; SMALL INTERFERING RNA; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; COWPOX VIRUS; CYTOKINE RELEASE; D5R GENE; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EMBRYO; FIBROBLAST CULTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INFECTION PREVENTION; KERATINOCYTE; LUNG CARCINOMA; MONKEYPOX VIRUS; NEWBORN; NUCLEOTIDE SEQUENCE; ORTHOPOXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALLPOX; VACCINIA VIRUS; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION; DOWN REGULATION; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; POXVIRUS INFECTION; RNA INTERFERENCE; TIME; TUMOR CELL LINE; VIROLOGY; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; COWPOX VIRUS; DOWN-REGULATION; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; HUMANS; INTERFERON-BETA; KERATINOCYTES; MONKEYPOX VIRUS; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 47249097139     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Fenner F. Smallpox, 'the most dreadful scourge of the human species'. Its global spread and recent eradication (2). Med J Aust 1984; 141:728-735.
2. Marcinak J, Vora, S, Weber S, et al. Household transmission of vaccinia virus from contact with a military smallpox vaccine - Illinois and Indiana, 2007. MMWR 2007; 56:478-481.
3. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis 2004; 4:15-25.
4. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 2000; 181:10-19.
5. Smee DF, Bailey KW, Wong MH, Sidwell RW. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res 2001; 52:55-62.
6. Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 2002; 46:1329-1335.
7. Mercer AA, Schmidt A and Weber O (Editors). Poxviruses. Birkhäuser Basel 2007; pp.375-395. [R Snoeck, G Andrei, E De Clercq (Series editors): Birkhäuser advances in infectious diseases].
8. Yang G, Pevear DC, Davies MH, Collen MS, Bailey T, Rippen S. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 2005; 79:13139-13149.
9. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002; 55:1-13.
10. Marris E. Dramatic rescue relieves rare case of smallpox infection. Nat Med 2007; 13:517.
11. Hammond SM. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett 2005; 579:5822-5829.
12. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15:188-200.
13. Nekhai S, Jerebtsova M. Therapies for HIV with RNAi. Curr Opin Mol Ther 2006; 8:52-61.
14. Takaku H. Gene silencing of HIV-1 by RNA interference. Antivir Chem Chemother 2004; 15:57-65.
15. Wu CJ, Huang HW, Liu CY, Hong CF, Chan YL. Inhibition of SARS-CoV replication by siRNA. Antiviral Res 2005; 65:45-48.
16. Li T, Zhang Y, Fu L, Yu C, Li X, Li Y. siRNA targeting the leader sequence of SARS-CoV inhibits virus replication. Gene Ther 2005; 12:751-761.
17. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005; 11:944-951.
18. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 2004; 101:8676-8681.
19. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A 2004; 101:8682-8686.
20. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11:50-55.
21. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21:639-644.
22. Smolic R, Volarevic M, Wu CH, Wu GY. Potential applications of siRNA in hepatitis C virus therapy. Curr Opin Investig Drugs 2006; 7:142-146.
23. Moss B. Poxviridae: the viruses and their replication. In Fields Virology, vol. 2. Edited by DM Knipe & PM Howley. 4th edn. Philadelphia: Lippincott Williams & Wilkins 2001; pp.2849-2883.
24. Garcel A, Crance JM, Drillien R, Garin D, Favier AL. Genomic sequence of a clonal isolate of the vaccinia virus Lister strain employed for smallpox vaccination in France and its comparison to other orthopoxviruses. J Gen Virol 2007; 88:1906-1916.
25. McDonald WF, Traktman P. Vaccinia virus DNA polymerase. In vitro analysis of parameters affecting processivity. J Biol Chem 1994; 269:31190-31197.
26. Stanitsa ES, Arps L, Traktman P. Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase. J Biol Chem 2006; 281:3439-3451.
27. Evans E, Klemperer N, Ghosh R, Traktman P. The vaccinia virus D5 protein, which is required for DNA replication, is a nucleic acid-independent nucleoside triphosphatase. J Virol 1995; 69:5353-5361.
28. Lin S, Chen W, Broyles SS. The vaccinia virus B1R gene product is a serine/threonine protein kinase. J Virol 1992; 66:2717-2723.
29. Gubser C, Hue S, Kellam P, Smith GL. Poxvirus genomes: a phylogenetic analysis. J Gen Virol 2004; 85:105-117.
30. Snoeck R, Holy A, Dewolf-Peeters C, Van Den Oord J, De Clercq E, Andrei G. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob Agents Chemother 2002; 46:3356-3361.
31. Ferrier A, Garin D, Crance JM. Rapid inactivation of vaccinia virus in suspension and dried on surfaces. J Hosp Infect 2004; 57:73-79.
32. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23:457-462.
33. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5:834-839.
34. Zheng BJ, Guan Y, Tang Q, Du C, Xie FY, He ML. Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir Ther 2004; 9:365-374.
35. Wiebusch L, Truss M, Hagemeier C. Inhibition of human cytomegalovirus replication by small interfering RNAs. J Gen Virol 2004; 85:179-184.
36. Evans E, Traktman P. Molecular genetic analysis of a vaccinia virus gene with an essential role in DNA replication. J Virol 1987; 61:3152-3162.
37. Boyle KA, Arps L, Traktman P. Biochemical and genetic analysis of the vaccinia virus d5 protein: multimerization-dependent ATPase activity is required to support viral DNA replication. J Virol 2007; 81:844-859.
38. De Silva FS, Lewis W, Berglund P, Koonin EV, Moss B. Poxvirus DNA primase. Proc Natl Acad Sci U S A 2007; 104:18724-18729.
39. Otaki M, Sada K, Kadoya H, Nagano-Fujii M, Hotta H. Inhibition of measles virus and subacute sclerosing panencephalitis virus by RNA interference. Antiviral Res 2006; 70:105-111.
40. Thanik VD, Greives MR, Lerman OZ, Seiser N, Dec W, Chang CC. Topical matrix-based siRNA silences local gene expression in a murine wound model. Gene Ther 2007; 14:1305-1308.
41. Barik S. Control of nonsegmented negative-strand RNA virus replication by siRNA. Virus Res 2004; 102:27-35.
42. Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci U S A 2003; 100:2718-2723.
43. Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, Hellermann G. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005; 11:56-62.
44. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006; 14:476-484.
45. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432:173-178.
46. Kumar P, Lee SK, Shankar P, Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med 2006; 3:e96.
47. Levine RS, Peterson AT, Yorita KL, Carroll D, Damon IK, Reynolds MG. Ecological niche and geographic distribution of human monkeypox in Africa. PLoS ONE 2007; 2:e176.
48. Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 2005; 41:1765-1771.
49. Pahlitzsch R, Hammarin AL, Widell A. A case of facial cellulitis and necrotizing lymphadenitis due to cowpox virus infection. Clin Infect Dis 2006; 43:737-742.
50. Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ. siRNA targeting vaccinia virus double-stranded RNA binding protein (E3L) exerts potent antiviral effects. Virology 2006; 348:489-497.
51. Lantermann M, Schwantes A, Sliva K, Sutter G, Schnierle BS. Vaccinia virus double-stranded RNA-binding protein E3 does not interfere with siRNA-mediated gene silencing in mammalian cells. Virus Res 2007; 126:1-8.
52. Valderrama F, Cordeiro JV, Schleich S, Frischknecht F, Way M. Vaccinia virus-induced cell motility requires FIIL-mediated inhibition of RhoA signaling. Science 2006; 311:377-381.